Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.

ABSTRACT: The development of immunotherapy, in particular immune checkpoint inhibitors (ICI), has revolutionized cancer treatment in the past decades. However, its efficacy is still limited to subgroups of patients with cancer. Therefore, effective treatment combination strategies are needed. Here, radiotherapy is highly promising, as it can induce immunogenic cell death, triggering the release of pro-inflammatory cytokines, thereby creating an immunogenic phenotype and sensitizing tumors to ICI. Recently, targeted radionuclide therapy (TRT) has attained significant interest for cancer treatment. In this approach, a tumor-targeting radiopharmaceutical is used to specifically deliver a therapeutic radiation dose to all tumor cells, including distant metastatic lesions, while limiting radiation exposu

SUBMITTER: Kleinendorst SC 

PROVIDER: S-EPMC9433955 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature